Sarcoma

Oncology
26
Pipeline Programs
23
Companies
26
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
4
12
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 27 programs with unclassified modality

Competitive Landscape

23 companies ranked by most advanced pipeline stage

CP
Chugai PharmaJapan - Tokyo
1 program
1
cisplatinPhase 31 trial
Active Trials
NCT00470223Active Not Recruiting318Est. Dec 2026
Novartis
NovartisBASEL, Switzerland
1 program
1
cisplatinPhase 31 trial
Active Trials
NCT01828099Completed376Est. Jan 2024
Design Therapeutics
3 programs
1
2
CMB305Phase 2
Combination of MK3475 with Metronomic CPPhase 2
CMB305Phase 1
Roche
RocheSTAVANGER NORWAY, Norway
3 programs
2
1
RG1507Phase 2
RO5045337Phase 11 trial
RO5045337Phase 11 trial
Active Trials
NCT01605526Completed23Est. Jun 2013
NCT01143740Completed20Est. Mar 2011
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
1
PTK787/ZK222584Phase 21 trial
Ra-223 DichloridePhase 1/22 trials
Active Trials
NCT02366130Completed45Est. Dec 2020
NCT01833520Completed18Est. Apr 2020
NCT00117299Completed45Est. Jan 2009
M&
Merck & Co.RAHWAY, NJ
2 programs
2
CMB305Phase 22 trials
Combination of MK3475 with Metronomic CPPhase 21 trial
Active Trials
NCT02609984Terminated89Est. Feb 2019
NCT02387125TerminatedEst. Mar 2019
NCT02406781Completed129Est. Jan 2023
Genentech
GenentechCA - Oceanside
1 program
1
CMB305Phase 2
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
CetuximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00148109Completed36Est. Dec 2009
AT
Actuate TherapeuticsFORT WORTH, TX
1 program
1
GemcitabinePhase 21 trial
Active Trials
NCT04906876WithdrawnEst. Jul 2025
Virogin Biotech
Virogin BiotechBC - Richmond
1 program
1
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 InjectionPhase 21 trial
Active Trials
NCT06126510RecruitingEst. Jan 2026
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
Talimogene LaherparepvecPhase 21 trial
Active Trials
NCT03069378Active Not Recruiting41Est. Mar 2026
Xencor
XencorPASADENA, CA
1 program
1
XmAb23104Phase 21 trial
Active Trials
NCT05879185TerminatedEst. Jul 2024
Bristol Myers Squibb
1 program
1
NivolumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT03465592Recruiting39Est. Mar 2029
PEEL Therapeutics
PEEL TherapeuticsUT - Salt Lake City
1 program
1
PEEL-224Phase 1/21 trial
Active Trials
NCT06709495RecruitingEst. Sep 2029
DS
Daiichi SankyoChina - Shanghai
1 program
1
PLX3397Phase 1/21 trial
Active Trials
NCT02584647Terminated39Est. Oct 2024
C
CuradevIndia - Noida
1 program
1
CRD3874Phase 11 trial
Active Trials
NCT06021626Recruiting72Est. Aug 2029
Precision BioSciences
1 program
1
GCAR1Phase 11 trial
Active Trials
NCT06813417Active Not Recruiting1Est. Jan 2030
Karyopharm Therapeutics
1 program
1
KCP-330Phase 11 trial
Active Trials
NCT01896505CompletedEst. Oct 2016
Acrotech Biopharma
Acrotech BiopharmaNJ - East Windsor
1 program
1
MarqiboPhase 11 trial
Active Trials
NCT01222780CompletedEst. Dec 2014
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
1
epirubicin hydrochloridePhase 11 trial
Active Trials
NCT00822848Completed18Est. Apr 2013
Alliance Pharmaceuticals
1 program
Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue SarcomaN/A1 trial
Active Trials
NCT00322855Terminated1Est. Aug 2007
E
EisaiChina - Liaoning
1 program
Palonosetron - Single DoseN/A1 trial
Active Trials
NCT00410488Completed51Est. Jun 2011
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
The Sarcoma Biology and Outcome ProjectN/A1 trial
Active Trials
NCT04758325Recruiting3,000Est. Dec 2032

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Novartiscisplatin
Chugai Pharmacisplatin
Virogin BiotechRecombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection
XencorXmAb23104
Actuate TherapeuticsGemcitabine
AmgenTalimogene Laherparepvec
Merck & Co.Combination of MK3475 with Metronomic CP
Merck & Co.CMB305
BayerRa-223 Dichloride
Eli Lilly and CompanyCetuximab
BayerPTK787/ZK222584
PEEL TherapeuticsPEEL-224
Bristol Myers SquibbNivolumab
Daiichi SankyoPLX3397
BayerRa-223 Dichloride

Showing 15 of 26 trials with date data

Clinical Trials (26)

Total enrollment: 4,361 patients across 26 trials

NCT01828099Novartiscisplatin

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Start: Jul 2013Est. completion: Jan 2024376 patients
Phase 3Completed
NCT00470223Chugai Pharmacisplatin

Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma

Start: Mar 2007Est. completion: Dec 2026318 patients
Phase 3Active Not Recruiting
NCT06126510Virogin BiotechRecombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection

Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Start: Jul 2023Est. completion: Jan 2026
Phase 2Recruiting
NCT05879185XencorXmAb23104

A Study of XmAb23104 in People With Sarcoma

Start: Apr 2023Est. completion: Jul 2024
Phase 2Terminated
NCT04906876Actuate TherapeuticsGemcitabine

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Start: Sep 2021Est. completion: Jul 2025
Phase 2Withdrawn
NCT03069378AmgenTalimogene Laherparepvec

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Start: Mar 2017Est. completion: Mar 202641 patients
Phase 2Active Not Recruiting
NCT02406781Merck & Co.Combination of MK3475 with Metronomic CP

Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial

Start: Jun 2015Est. completion: Jan 2023129 patients
Phase 2Completed
NCT02609984Merck & Co.CMB305

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Start: Apr 2015Est. completion: Feb 201989 patients
Phase 2Terminated
NCT02366130BayerRa-223 Dichloride

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Start: Feb 2015Est. completion: Dec 202045 patients
Phase 2Completed
NCT00148109Eli Lilly and CompanyCetuximab

Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas

Start: Jun 2005Est. completion: Dec 200936 patients
Phase 2Completed
NCT00117299BayerPTK787/ZK222584

PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib

Start: Sep 2004Est. completion: Jan 200945 patients
Phase 2Completed
NCT06709495PEEL TherapeuticsPEEL-224

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Start: Jan 2025Est. completion: Sep 2029
Phase 1/2Recruiting
NCT03465592Bristol Myers SquibbNivolumab

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

Start: May 2018Est. completion: Mar 202939 patients
Phase 1/2Recruiting
NCT02584647Daiichi SankyoPLX3397

PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Start: Nov 2015Est. completion: Oct 202439 patients
Phase 1/2Terminated
NCT01833520BayerRa-223 Dichloride

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Start: Oct 2013Est. completion: Apr 202018 patients
Phase 1/2Completed
NCT06813417Precision BioSciencesGCAR1

CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma

Start: Jan 2025Est. completion: Jan 20301 patients
Phase 1Active Not Recruiting
NCT06021626CuradevCRD3874

A Study of CRD3874-SI in People With Solid Tumors

Start: Aug 2023Est. completion: Aug 202972 patients
Phase 1Recruiting
NCT02387125Merck & Co.CMB305

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Start: Feb 2015Est. completion: Mar 2019
Phase 1Terminated
NCT01896505Karyopharm TherapeuticsKCP-330

A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma

Start: Jul 2013Est. completion: Oct 2016
Phase 1Completed
NCT01605526RocheRO5045337

A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma

Start: May 2012Est. completion: Jun 201323 patients
Phase 1Completed
NCT01222780Acrotech BiopharmaMarqibo

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Start: Sep 2010Est. completion: Dec 2014
Phase 1Completed
NCT01143740RocheRO5045337

A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery

Start: Jun 2010Est. completion: Mar 201120 patients
Phase 1Completed
NCT00822848Knight Therapeuticsepirubicin hydrochloride

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

Start: Feb 2009Est. completion: Apr 201318 patients
Phase 1Completed
NCT04758325Heidelberg PharmaThe Sarcoma Biology and Outcome Project

The Sarcoma Biology and Outcome Project

Start: Jul 2019Est. completion: Dec 20323,000 patients
N/ARecruiting
NCT00410488EisaiPalonosetron - Single Dose

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

Start: Dec 2006Est. completion: Jun 201151 patients
N/ACompleted
NCT00322855Alliance PharmaceuticalsChart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma

Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma

Start: Aug 2005Est. completion: Aug 20071 patients
N/ATerminated

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
5h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
7h ago

Executive Medical Director, Oncology Early Development

AbbVie
Florham Park, NJ
7h ago

Executive Medical Director, Oncology Early Development

AbbVie
South San Francisco, CA
7h ago

Executive Medical Director, Oncology Early Development

AbbVie
North Chicago, IL
7h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
5 actively recruiting trials targeting 4,361 patients
23 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)